Breaking Finance News

ValuEngine downgraded NewLink Genetics Corp (NASDAQ:NLNK) to Sell in a report released today.

Yesterday NewLink Genetics Corp (NASDAQ:NLNK) traded -2.04% lower at $12.59. The company’s 50-day moving average is $11.21 and its 200-day moving average is $11.01. The last stock close price is up -8.46% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 956,017 shares of the stock were exchanged, down from an average trading volume of 2,666,400

ValuEngine has downgraded NewLink Genetics Corp (NASDAQ:NLNK) to Sell in a report released on 06/02/2017.

See Chart Below

NewLink Genetics Corp (NASDAQ:NLNK)

NewLink Genetics Corp has a 52 week low of $5.90 and a 52 week high of $25.17 The company’s market cap is currently $0.

In addition to ValuEngine reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $34.33 with 2 firms rating the stock a strong buy, 3 firms rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About NewLink Genetics Corp (NASDAQ:NLNK)

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.